PubMed ID: 31577084
Author(s): Elnahry AG, Elnahry GA. REVERSIBLE NEUROTROPHIC KERATOPATHY ASSOCIATED WITH ROSUVASTATIN THERAPY: A CASE REPORT. J Popul Ther Clin Pharmacol. 2019 Aug 16;26(2):e38-e42. doi: 10.15586/jptcp.v26i2.627. PMID 31577084
Journal: Journal Of Population Therapeutics And Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique, Volume 26, Issue 2, Aug 2019
BACKGROUND Rosuvastatin is a 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme inhibitor that is in wide use with few reported ocular adverse events.
OBJECTIVES To report a case of bilateral neurotrophic keratopathy associated with rosuvastatin therapy that dramatically improved following drug discontinuation.
CASE PRESENTATION A 65-year-old female presented with painless diminution of vision in both eyes of gradual onset and progressive course for 1 month. She had recently started rosuvastatin therapy for hyperlipidemia. Examination revealed bilateral stage 2 neurotrophic keratopathy with impaired corneal sensation which was previously resistant to conservative ulcer treatment. Following discontinuation of rosuvastatin therapy, there was dramatic bilateral improvement in corneal sensation, size of the corneal ulcers, and visual acuity.
CONCLUSION Rosuvastatin may result in reversible trigeminal nerve impairment and neurotrophic keratopathy.
© 2019 Journal of Population Therapeutics and Clinical Pharmacology. All rights reserved.